Earnings summaries and quarterly performance for Entrada Therapeutics.
Executive leadership at Entrada Therapeutics.
Board of directors at Entrada Therapeutics.
Research analysts covering Entrada Therapeutics.
Recent press releases and 8-K filings for TRDA.
Entrada Therapeutics Highlights 2026 Clinical Milestones and Financial Position at TD Cowen Conference
TRDA
New Projects/Investments
Guidance Update
- Entrada Therapeutics expects four potential clinical readouts in 2026 from its Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) programs, including data from its DMD exon 44 program in Q2 2026 and by year-end 2026, and DM1 data by mid-2026.
- The company's cash runway extends into Q3 2027 with approximately $296 million on its balance sheet, not including up to $485 million in potential DM1 milestones from its partnership with Vertex.
- Entrada is expanding its pipeline into an ocular disease franchise with its Usher syndrome program (ENTR-801) and plans to advance five clinical stage programs by the end of 2026.
- The DMD programs are designed to support a U.S. Accelerated Approval pathway, targeting a U.S. market of roughly $5 billion with proprietary and differentiated therapeutics.
3 days ago
Entrada Therapeutics Outlines 2026 Clinical Milestones and Financial Position
TRDA
New Projects/Investments
Guidance Update
- Entrada Therapeutics anticipates four potential clinical readouts in 2026 from its Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) programs, including exon 44 and exon 45 studies, with the first exon 44 data expected in Q2 2026.
- The company has a cash runway into Q3 2027 with approximately $296 million on the balance sheet.
- Its DM1 partnership with Vertex provides access to up to $485 million in milestones, none of which are included in the current cash runway.
- Entrada is expanding its pipeline into the ocular disease franchise with its Usher syndrome program (ENTR-801), which is entering IND-enabling studies in 2026.
- For its DMD programs, Entrada aims for a U.S. Accelerated Approval pathway and expects its 12 mg/kg dose for the ENTR-601-44 program to surpass 25% dystrophin production by year-end, exceeding competitor results.
3 days ago
Entrada Therapeutics Outlines 2026 Clinical Milestones and Financial Position
TRDA
Guidance Update
New Projects/Investments
- Entrada Therapeutics anticipates four potential clinical readouts in 2026 from its DMD and DM1 programs, including data for exon 44 in Q2 2026 and by year-end 2026, and for exon 45 in mid-2026.
- For its ENTR-601-44 (DMD exon 44) program, the company expects double-digit dystrophin production from the first cohort in Q2 2026, with the second cohort aiming to surpass 25% dystrophin production by year-end.
- The cash runway for Entrada extends into Q3 2027, backed by approximately $296 million on the balance sheet and up to $485 million in potential DM1 milestones from its Vertex partnership.
- Vertex is on track to complete dosing for the Phase II MAD study of VX-670 (DM1 program) in mid-2026, and Entrada is expanding its pipeline into ocular diseases with the Usher syndrome program (ENTR-801).
3 days ago
Entrada Therapeutics Reports Q4 and Full Year 2025 Financial Results and Clinical Pipeline Updates
TRDA
Earnings
Guidance Update
New Projects/Investments
- Entrada Therapeutics reported a net loss of $(39.2) million for the fourth quarter of 2025 and $(143.8) million for the full year 2025, compared to net income in the same periods of 2024. This was primarily driven by a significant decrease in collaboration revenue, which was $1.3 million for Q4 2025 and $25.4 million for the full year 2025.
- The company's cash, cash equivalents, and marketable securities stood at $295.7 million as of December 31, 2025, and its cash runway is expected to extend into Q3 2027.
- Entrada is on track to report ELEVATE-44-201 data from Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026, and ELEVATE-45-201 data from Cohort 1 in mid-2026. An Independent Data Monitoring Committee recommended initiating Cohort 2 of the ELEVATE-44-201 study at an increased dose.
- The company is expanding its preclinical pipeline, having nominated ENTR-801 for Usher syndrome type 2A and planning to nominate a second clinical candidate in inherited retinal diseases later in 2026.
Feb 26, 2026, 12:04 PM
Entrada Therapeutics Outlines Data-Rich 2026 with Key Clinical Inflection Points
TRDA
Guidance Update
New Projects/Investments
- Entrada Therapeutics anticipates a data-rich year in 2026 with multiple clinical inflection points for its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs.
- The company expects to announce the first clinical data set for its ENTR-601-44 DMD program (6 mg/kg dose) in Q2 2026, targeting double-digit dystrophin levels and re-establishing safety.
- Additional DMD data for ENTR-601-45 is expected in mid-2026, and for ENTR-601-44 (up to 12 mg/kg dose) by the end of 2026.
- The successful Q2 2026 data for ENTR-601-44 would be a significant de-risking event for its other DMD programs (45, 50, and 51) due to the shared endosomal escape vehicle (EEV) technology.
- Entrada plans to assess the Q2 2026 data and discuss with the FDA to potentially increase the dose for its U.S. adult study, which is currently capped at 1.28 mg/kg.
Feb 11, 2026, 9:00 PM
Entrada Therapeutics Outlines Data-Rich 2026 with Key Clinical Milestones for DMD and DM1 Programs
TRDA
New Projects/Investments
Guidance Update
- Entrada Therapeutics anticipates a data-rich 2026, with the first clinical data for its ENTR-601-44 Duchenne muscular dystrophy (DMD) program expected in Q2 2026, targeting double-digit dystrophin levels at a 6 mg/kg dose.
- Additional clinical data for ENTR-601-44 (up to 12 mg/kg) and the first cohort data for ENTR-601-45 are also expected by the end of 2026 and mid-2026, respectively.
- The company's proprietary endosomal escape vehicle (EEV) delivery mechanism is a key de-risking factor for its DMD programs (exons 44, 45, 50, 51) and the myotonic dystrophy type 1 (DM1) collaboration with Vertex, as the same EEV is utilized across these programs.
- Entrada plans to enroll an adult study in the U.S. in the second half of 2026, but will first evaluate the Q2 2026 data and engage with the FDA to potentially increase the currently capped dose of 1.28 mg/kg.
Feb 11, 2026, 9:00 PM
Entrada Therapeutics Outlines 2026 Clinical Data Milestones
TRDA
New Projects/Investments
Guidance Update
- Entrada Therapeutics is focused on developing intracellular therapeutics for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), utilizing proprietary endosomal escape vehicles (EEVs). The company also recently announced its entry into ocular diseases, specifically Usher syndrome type 1A.
- The company anticipates a data-rich year in 2026, with several clinical data inflection points for its DMD programs.
- The first clinical data set for ENTR-601-44 (6 mg/kg dose) is expected in Q2 2026, with expectations of double-digit dystrophin levels and re-establishment of safety.
- Additional DMD program data includes the first cohort of ENTR-601-45 in mid-2026 and data for the 12 mg/kg dose of ENTR-601-44 before the end of 2026.
- The partner program VX-670 for DM1 with Vertex is projected to complete dosing and enrollment by mid-2026.
Feb 11, 2026, 9:00 PM
Entrada Therapeutics Highlights 2026 Clinical Milestones and Ocular Pipeline Expansion
TRDA
Guidance Update
New Projects/Investments
- Entrada Therapeutics anticipates several value-driving catalysts in 2026, including top-line data from the first cohort of its ENTR-601-44 program in Q2 2026, first cohort data for ENTR-601-45 in mid-2026, and the completion of enrollment and dosing for the VX-670 program (partnered with Vertex) also in mid-2026.
- The company is expanding its focus into ocular diseases, having nominated ENTR-801 as its first clinical candidate for Usher syndrome type 2A, with plans to announce another clinical candidate in 2026.
- Entrada ended 2025 with approximately $296 million on its balance sheet, providing a cash runway into Q3 2027.
- Entrada's strategy for its Duchenne muscular dystrophy (DMD) programs involves running studies outside the U.S. to collect data, aiming for double-digit dystrophin production in the ENTR-601-44 program, and then pursuing accelerated approval in the U.S..
Jan 14, 2026, 11:45 PM
Entrada Therapeutics Highlights 2026 Catalysts and Financial Position at J.P. Morgan Healthcare Conference
TRDA
Product Launch
New Projects/Investments
Guidance Update
- Entrada Therapeutics anticipates several value-driving catalysts in 2026, including top-line data from the first cohort of its ENTR-601-44 program in Q2 2026, first cohort data for ENTR-601-45 in mid-2026, and completion of enrollment and dosing for the VX-670 DM1 program with Vertex by mid-2026.
- The company ended 2025 with $296 million on its balance sheet, providing a cash runway into Q3 2027.
- Entrada has expanded its focus into ocular diseases, nominating ENTR-801 for Usher syndrome type 2A as its first clinical candidate in this area, with plans for a second candidate in 2026.
- The partnership with Vertex for the VX-670 DM1 program included $224 million upfront, a $26 million equity investment, and potential for $485 million in milestones.
Jan 14, 2026, 11:45 PM
Entrada Therapeutics Highlights Progress and Upcoming Milestones in 2026
TRDA
New Projects/Investments
Guidance Update
- Entrada Therapeutics anticipates multiple clinical data readouts in 2026 for its Duchenne muscular dystrophy (DMD) programs, including top-line data for ENTR-601-44 in Q2 2026 and for ENTR-601-45 in mid-2026.
- The company's partnership with Vertex for the myotonic dystrophy type 1 (DM1) program, VX-670, expects completion of enrollment and dosing for the multiple ascending dose portion by mid-2026.
- Entrada announced an expansion into ocular diseases, nominating ENTR-801 for Usher syndrome type 2A, and plans to announce another clinical candidate in this area in 2026.
- Entrada ended 2025 with $296 million on its balance sheet, providing a cash runway into Q3 2027.
Jan 14, 2026, 11:45 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more